Abeona Therapeutics Announces Leadership Appointments with Max Colao as Chief Commercial Officer NEW YORK and CLEVELAND

Abeona Therapeutics Announces

Appointments with Max Colao as Chief Commercial Officer

NEW YORK and CLEVELAND - July

26, 2018: Abeona Therapeutics Inc. (NASDAQ: ABEO), a leading clinical- stage biopharmaceutical company focused on developing

novel cell and gene therapies for life-threatening rare genetic diseases, today announced the appointment of Max Colao as Chief

Commercial Officer. Mr. Colao has more than 20 years of global pharmaceutical and biotechnology experience, having most recently

served as the Senior Vice President of US Commercial Operations at Alexion Pharmaceuticals, Inc. The Company also announced Jeffrey

B. Davis will be stepping down from his role as Chief Operating Officer at the end of the quarter to ensure a smooth transition.

In an ongoing commitment to enhance the capabilities of its senior team, Abeona recently appointed Kristina Maximenko as Global

Head of Human Resources.

"With our pipeline maturing toward

commercial stages, we're focused on building a strong team to deliver on our ambitious goals," stated Carsten Thiel,

Ph.D., Abeona's Chief Executive Officer. "I am excited to welcome Max to our organization given his broad commercial

experience and deep understanding of the healthcare industry. We are pleased to have Kristina on board, who will help us continue

building a vibrant culture and engaged workforce. Finally, I would like to thank Jeff for his work over many years with our company."

In his most recent role at Alexion, Mr.

Colao led a team of several hundred people and was responsible for $2 billion in sales across three franchises. Mr. Colao has an

extensive track record of successful innovative and competitive biotechnology launches in oncology, nephrology, rheumatology, and

ultra-rare diseases. He earlier served as Vice President of the US Metabolic Disorders Business Unit where he established Alexion's

second business unit and launched two novel enzyme replacement therapies including the successful launch of Strensiq .

Prior to Alexion, Mr. Colao spent 18 years at Amgen, where he held roles of increasing responsibility in global sales and marketing,

departing in 2013 as Vice President of Inflammation Sales. Mr. Colao earned his MBA from the University of Southern California

in Los Angeles and his undergraduate degree from the University of California, Los Angeles, with a Bachelor of Science in Applied

Mathematics and Economics.

"I am very pleased to join Abeona

at this exciting time and look forward to building a fully-integrated commercial organization focused on bringing important new

therapies to patients suffering from devastating rare genetic disorders with vast unmet medical needs, " said Mr. Colao.

Ms. Maximenko has more than 15 years of

human resources experience, having most recently served as the Global HR Director for Advanced Accelerator Applications (AAAP),

a Novartis company. Prior to Novartis' acquisition of AAAP, she served as a strategic human resources partner and global

HR lead responsible for more than 700 employees operating in a matrix environment within 11 International locations and in more

than 20 US states. Ms. Maximenko is trained in employment law, receiving her Master of Laws degree in International Law from Far

Eastern National University with additional certifications in Human Resources.

"We look forward to working closely

with Max and Kristina whose experience will greatly enhance our senior leadership team during this exciting time," stated

Steven H. Rouhandeh, Executive Chairman at Abeona. "As one of the original employees at Abeona, Jeff has made a significant

impact on the organization's progress since inception. On behalf of the Board of Directors, we would like to collectively

extend our gratitude to Jeff for his many contributions to Abeona over the past several years."

About Abeona: Abeona Therapeutics

Inc. is a clinical-stage biopharmaceutical company developing cell and gene therapies for life- threatening rare genetic diseases.

Abeona's lead programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102

(AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and ABO-101 (AAV-NAGLU),

an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type B (MPS IIIB). Abeona is also developing ABO-201

(AAV-CLN3) gene therapy for CLN3 disease, ABO-202 (AAV-CLN1) for treatment of CLN1 disease, EB-201 for epidermolysis bullosa (EB),

ABO-301 (AAV-FANCC) for Fanconi anemia (FA) disorder and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene

therapy for rare blood diseases. In addition, Abeona is developing a proprietary vector platform, AIM , for next generation

product candidates. For more information, visit www.abeonatherapeutics.com.

Christine Silverstein

SVP, Finance & Investor Relations

Abeona Therapeutics Inc.

Berry & Company Public Relations

This press release contains certain

statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve

risks and uncertainties. These statements include statements regarding our pipeline maturing toward commercial stages; our expectation

that the broad experience, deep understanding of the healthcare industry, development of high performing teams, effective resource

allocation and proven ability to achieve ambitious outcomes by Max Colao and Kristina Maximenko will serve our growing commercial

focus well; and our expectation that we will build a commercial organization focused on bringing new therapies to patients suffering

from devastating rare genetic disorders. We have attempted to identify forward looking statements by such terminology as "may,"

will," "anticipate," "believe," "estimate," "expect," "intend,"

and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances), which constitute

and are intended to identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking

statements as a result of various important factors, numerous risks and uncertainties, including but not limited to continued interest

in our rare disease portfolio, our ability to enroll patients in clinical trials, the impact of competition; the ability to develop

our products and technologies; the ability to achieve or obtain necessary regulatory approvals and licenses; the impact of changes

in the financial markets and global economic conditions; and other risks as may be detailed from time to time in the Company's

Annual Reports on Form 10-K and other reports filed by the Company with the Securities and Exchange Commission. The Company undertakes

no obligations to make any revisions to the forward-looking statements contained in this release or to update them to reflect events

or circumstances occurring after the date of this release, whether as a result of new information, future developments or otherwise.